iRhythm Technologies (NASDAQ:IRTC) Shares Down 6.5% on Analyst Downgrade

Shares of iRhythm Technologies (NASDAQ:IRTC) dropped 6.5% on Friday after Wells Fargo & Company lowered their price target on the stock from $200.00 to $180.00. Wells Fargo & Company currently has an overweight rating on the stock. iRhythm Technologies traded as low as $120.06 and last traded at $120.7760. Approximately 209,752 shares traded hands during trading, a decline of 66% from the average daily volume of 619,346 shares. The stock had previously closed at $129.16.

IRTC has been the topic of a number of other research reports. Freedom Capital raised iRhythm Technologies to a “strong-buy” rating in a research report on Thursday, January 15th. Canaccord Genuity Group dropped their price objective on shares of iRhythm Technologies from $212.00 to $198.00 and set a “buy” rating on the stock in a report on Friday, February 20th. Morgan Stanley reaffirmed an “overweight” rating on shares of iRhythm Technologies in a research report on Monday, January 12th. Wall Street Zen cut shares of iRhythm Technologies from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Citigroup cut their price objective on shares of iRhythm Technologies from $242.00 to $214.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, iRhythm Technologies currently has a consensus rating of “Moderate Buy” and a consensus target price of $202.23.

Insider Activity

In other news, EVP Sumi Shrishrimal sold 2,830 shares of the business’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $128.44, for a total transaction of $363,485.20. Following the transaction, the executive vice president directly owned 41,870 shares in the company, valued at $5,377,782.80. The trade was a 6.33% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mervin Smith sold 1,352 shares of the company’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $128.44, for a total transaction of $173,650.88. Following the completion of the sale, the executive vice president directly owned 25,612 shares in the company, valued at approximately $3,289,605.28. The trade was a 5.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 94,509 shares of company stock worth $12,734,195. 1.10% of the stock is currently owned by company insiders.

Key iRhythm Technologies News

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q1 results beat expectations: iRhythm reported EPS of ($0.35) vs. consensus ($0.66) and revenue of $199.4M (vs. $194.1M est.), with revenue up ~25.6% YoY — this shows improving top-line momentum and narrower losses. MarketBeat Q1 results
• Positive Sentiment: Analyst bullishness: Needham raised its price target to $255 and kept a Buy rating, signaling strong upside expectations from some sell‑side analysts. Benzinga note on Needham
• Positive Sentiment: Market expansion, margin gains and AI/regulatory tailwinds highlighted in recent coverage — these catalysts could support longer‑term revenue and margin improvement if execution continues. MSN deep dive
• Neutral Sentiment: FY‑2026 revenue guidance was provided (~$875–$885M), which is essentially in line with consensus (~$876M); EPS guidance was unclear in the release — mixed signal that tempers the beat. Company press release / slide deck
• Neutral Sentiment: Full Q1 materials and the earnings call transcript are available for deeper due diligence (useful for evaluating management commentary on margins, utilization and reimbursement). Seeking Alpha transcript
• Negative Sentiment: Not all analysts are upbeat — Truist cut its price target in a healthcare sector preview, reflecting more cautious sentiment that could weigh on near‑term shares. Yahoo/Truist note
• Negative Sentiment: Company remains unprofitable with negative net margin and ROE; investors sensitive to profitability timelines may sell into the beat, keeping pressure on the stock. Zacks coverage

Institutional Investors Weigh In On iRhythm Technologies

Institutional investors and hedge funds have recently modified their holdings of the company. Root Financial Partners LLC bought a new stake in shares of iRhythm Technologies in the 3rd quarter valued at about $30,000. Measured Wealth Private Client Group LLC bought a new stake in shares of iRhythm Technologies in the 3rd quarter valued at about $30,000. GAMMA Investing LLC raised its holdings in shares of iRhythm Technologies by 48.4% in the 4th quarter. GAMMA Investing LLC now owns 184 shares of the company’s stock valued at $33,000 after purchasing an additional 60 shares during the period. Smartleaf Asset Management LLC raised its holdings in shares of iRhythm Technologies by 100.0% in the 3rd quarter. Smartleaf Asset Management LLC now owns 198 shares of the company’s stock valued at $34,000 after purchasing an additional 99 shares during the period. Finally, FNY Investment Advisers LLC bought a new stake in shares of iRhythm Technologies in the 3rd quarter valued at about $34,000.

iRhythm Technologies Stock Performance

The company has a market capitalization of $4.00 billion, a P/E ratio of -84.56 and a beta of 1.18. The stock’s fifty day moving average price is $122.93 and its 200-day moving average price is $154.60. The company has a debt-to-equity ratio of 4.25, a quick ratio of 4.48 and a current ratio of 4.63.

iRhythm Technologies (NASDAQ:IRTC) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.66) by $0.31. The company had revenue of $199.39 million for the quarter, compared to analyst estimates of $194.11 million. iRhythm Technologies had a negative net margin of 5.96% and a negative return on equity of 28.15%. The company’s revenue was up 25.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.97) earnings per share. As a group, research analysts anticipate that iRhythm Technologies will post -0.16 EPS for the current fiscal year.

About iRhythm Technologies

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.